Worldwide: Healthcare

Healthcare real estate rewards lawyers who understand the business strategy behind the asset, not just the documents that close the deal. In this episode of "Counsel That Cares," Morgan Ribeiro speaks with John Bryant, the recently retired general counsel of Healthcare Realty Trust, about the evolution of outpatient care, risk management in large-scale growth and what in-house teams need from outside counsel.

The FDA has issued 25 warning letters to telehealth companies for allegedly making false or misleading claims about compounded GLP-1 drugs on their websites. These enforcement actions target promotional practices that suggest FDA approval or equivalence to approved products, marking an escalation in the agency's crackdown on compounded weight loss medications.

On July 7, the Centers for Medicare & Medicaid Services (CMS) published a proposal to cut Medicare Part B payment rates to certain hospitals in the 340B drug pricing program for separately payable drugs purchased...

This digest covers key virtual and digital health regulatory and public policy developments during May and early June 2026 from the United States, United Kingdom, and European Union.

The Trump administration has intensified scrutiny of hospital-payor contracts through coordinated policy and enforcement actions, targeting provisions that allegedly limit patient choice and inflate healthcare costs. A White House economic analysis estimates that banning anti-steering, anti-tiering, and all-or-nothing contracting provisions could reduce hospital prices by up to 18% in certain markets, while the Department of Justice has secured its first settlement with OhioHealth and pursues similar litiga

Moderna's investigational mRNA influenza vaccine, mRNA-1010, received unanimous support from the FDA's advisory committee based on Phase 3 clinical trial data involving over 40,000 participants. The committee determined that the vaccine's benefits outweigh its risks for adults aged 50 and older, marking a significant milestone in the regulatory review process. The FDA will now consider this recommendation as part of its evaluation, with a decision expected by August 2026.

The Department of Justice's 2026 National Health Care Fraud Takedown charged 455 defendants in connection with $6.5 billion in alleged fraud schemes, marking an unprecedented scale of enforcement action. This whole-of-government approach leverages advanced data analytics and international cooperation to combat healthcare fraud across Medicare, Medicaid, and other federal programs. The enforcement action demonstrates heightened scrutiny of providers, aggressive asset forfeiture, and a focus on cases involvin

Medicare Advantage enforcement has shifted from scattered whistleblower actions into a predictable regulatory pattern driven by encounter data analytics. Former HHS Inspector General Christi Grimm and federal prosecutor Giselle Joffre examine how reverse false claim theories now anchor enforcement, why compliance programs frequently fail, and what the accelerating use of AI and data analytics means for health plans facing systematic scrutiny of risk adjustment practices.

Federal enforcers are deploying aggressive new investigative tactics against providers of gender-affirming care for minors, using misbranding theories and sweeping subpoenas that raise serious questions about data use and prosecutorial purpose. As courts push back on some federal overreach, hospitals find themselves caught between antidiscrimination mandates and physician autonomy, with the Colorado Children's case illustrating the impossible bind providers now face.